Moderna mRNA-1769 outperforms MVA and ACAM2000 in primate mpox challenge study
Start here
A head-to-head non-human primate study published in Cell compared three mpox vaccine candidates — Moderna's lipid nanoparticle mRNA vaccine mRNA-1769, MVA and ACAM2000 — after a lethal clade 1 intravenous challenge. Both mRNA-1769 and MVA prevented deaths, while all controls died. mRNA-1769, which targets four conserved orthopoxvirus epitopes, produced about 50 to 60 total skin lesions, versus about 600 for MVA and about 1600 in unvaccinated controls. The trial was industry-run, and intravenous challenge does not model natural human infection, so the results need confirmation from independent post-marketing data.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comCell study in primates compares Moderna mRNA-1769, MVA and ACAM2000 mpox vaccines
A head-to-head non-human primate study published in Cell compared three mpox vaccine candidates after lethal clade 1 intravenous challenge: MVA and Moderna's lipid nanoparticle mRNA vaccine mRNA-1769 both prevented deaths while all controls died. mRNA-1769, targeting four conserved orthopoxvirus epitopes, produced about 50 to 60 total skin lesions versus about 600 for MVA and about 1600 in controls. The trial was industry-run, and intravenous challenge does not model natural human infection, so independent post-marketing data are needed.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.